ArticleFrontiers in pharmacology2022
Editorial: Cancer therapy: The challenge of handling a double-edged sword.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors.Current drug delivery · 2026Review
- Investigation of the role of microtubule on the activity of the mitotic kinesin EG5 using multiscale modelling: unravelling molecular mechanisms.Journal of computer-aided molecular design · 2025Article
- Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Chemotherapy-Induced Neuropathy Affecting the Gastrointestinal Tract.Neurogastroenterology and motility · 2025Review
- Glucocorticoids Downregulate PD-L1 in Glioblastoma Cells via GILZ-Mediated ERK Inhibition.Biomedicines · 2025Article
- Overcoming Clusterin-Induced Chemoresistance in Cancer: A Computational Study Using a Fragment-Based Drug Discovery Approach.Biology · 2025Article
- Piperazine-Substituted Pyranopyridines Exhibit Antiproliferative Activity and Act as Inhibitors of HBV Virion Production.International journal of molecular sciences · 2025Article
- An up-To-Date Review of Elesclomol and Its Nano-Formulations in Cancer Therapy.Cancer reports (Hoboken, N.J.) · 2025Review
- Exploring the Anticancer Potential of PhenolicInternational journal of molecular sciences · 2024Article
- Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysis.Journal of cancer survivorship : research and practice · 2024Article
- Contractility of isolated colonic smooth muscle strips from rats treated with cancer chemotherapy: differential effects of cisplatin and vincristine.Frontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.